Molecular Therapy, ISSN 1525-0016, 01/2014, Volume 22, Issue 1, pp. 42 - 51
Self-complementary adeno-associated viral (AAV) vectors expressing human factor IX (hF.IX) have achieved transient or sustained correction of hemophilia B in...
EFFICIENT TRANSDUCTION | MEDICINE, RESEARCH & EXPERIMENTAL | AAV VECTORS | EFFICACY | SAFETY | HUMAN FIX | SEROTYPE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IMMUNE-RESPONSES | FACTOR-IX | GENETICS & HEREDITY | MICE | LIVER TRANSDUCTION | Dependovirus - genetics | Transduction, Genetic | Genetic Vectors - immunology | Humans | Dependovirus - immunology | Male | Epitopes, T-Lymphocyte | Genetic Vectors - standards | Genetic Vectors - genetics | Capsid - immunology | Lymphocyte Activation - immunology | Animals | Capsid Proteins - immunology | T-Cell Antigen Receptor Specificity | Immunologic Memory | Mice | CD8-Positive T-Lymphocytes - immunology | Genome | Quality Control | Original
EFFICIENT TRANSDUCTION | MEDICINE, RESEARCH & EXPERIMENTAL | AAV VECTORS | EFFICACY | SAFETY | HUMAN FIX | SEROTYPE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IMMUNE-RESPONSES | FACTOR-IX | GENETICS & HEREDITY | MICE | LIVER TRANSDUCTION | Dependovirus - genetics | Transduction, Genetic | Genetic Vectors - immunology | Humans | Dependovirus - immunology | Male | Epitopes, T-Lymphocyte | Genetic Vectors - standards | Genetic Vectors - genetics | Capsid - immunology | Lymphocyte Activation - immunology | Animals | Capsid Proteins - immunology | T-Cell Antigen Receptor Specificity | Immunologic Memory | Mice | CD8-Positive T-Lymphocytes - immunology | Genome | Quality Control | Original
Journal Article
2.
Full Text
CRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Biotechnology Journal, ISSN 1860-6768, 11/2014, Volume 9, Issue 11, pp. 1402 - 1412
Its remarkable ease and efficiency make the CRISPR (clustered regularly interspaced short palindromic repeats) DNA editing machinery highly attractive as a new...
CRISPR | Viral vectors | Genome engineering | AAV | Gene editing | CELLS | IMMUNITY | BIOCHEMICAL RESEARCH METHODS | CAS SYSTEMS | GUIDE | ENDONUCLEASE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | LIVER | GENE-THERAPY | MUTATIONS | VIRUS VECTORS | Genetic Engineering - methods | Dependovirus - genetics | Animals | Base Sequence | Humans | HEK293 Cells | Molecular Sequence Data | Mice | MicroRNAs - genetics | Binding Sites | CRISPR-Cas Systems - genetics | Genetic Vectors - genetics | Genetic vectors | RNA | Genomics | Genetically modified organisms | Genetic engineering | Cross infection | Nosocomial infections | T cells | Health aspects
CRISPR | Viral vectors | Genome engineering | AAV | Gene editing | CELLS | IMMUNITY | BIOCHEMICAL RESEARCH METHODS | CAS SYSTEMS | GUIDE | ENDONUCLEASE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | LIVER | GENE-THERAPY | MUTATIONS | VIRUS VECTORS | Genetic Engineering - methods | Dependovirus - genetics | Animals | Base Sequence | Humans | HEK293 Cells | Molecular Sequence Data | Mice | MicroRNAs - genetics | Binding Sites | CRISPR-Cas Systems - genetics | Genetic Vectors - genetics | Genetic vectors | RNA | Genomics | Genetically modified organisms | Genetic engineering | Cross infection | Nosocomial infections | T cells | Health aspects
Journal Article
Gene Therapy, ISSN 0969-7128, 10/2004, Volume 11, Issue S1, pp. S10 - S17
Circumventing the immune response to the vector is a major challenge with all vector types. Viral vectors are the most likely to induce an immune response,...
Innate immunity | Specific immunity | AAV | MEDICINE, RESEARCH & EXPERIMENTAL | HUMAN DENDRITIC CELLS | RECOMBINANT ADENOASSOCIATED VIRUS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CD40 LIGAND | ADENOVIRAL VECTORS | CYTOTOXIC T-LYMPHOCYTES | innate immunity | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VIVO | PLASMID DNA | TRANSIENT IMMUNOSUPPRESSION | FACTOR-IX | GENETICS & HEREDITY | TRANSGENE PRODUCT | specific immunity | Immune System - physiology | Genetic Vectors - administration & dosage | Genetic Vectors - immunology | Humans | DNA, Bacterial - immunology | Immunosuppression | Animals | Leukocytes, Mononuclear - immunology | Adenoviridae - genetics | Antibodies, Bacterial - immunology | Adenoviridae - immunology | Transduction, Genetic - methods | Cytokines - immunology | Genetic Therapy - adverse effects | Genetic Therapy - methods | Physiological aspects | Immune response | Genetic vectors | Gene therapy | Health aspects
Innate immunity | Specific immunity | AAV | MEDICINE, RESEARCH & EXPERIMENTAL | HUMAN DENDRITIC CELLS | RECOMBINANT ADENOASSOCIATED VIRUS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CD40 LIGAND | ADENOVIRAL VECTORS | CYTOTOXIC T-LYMPHOCYTES | innate immunity | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VIVO | PLASMID DNA | TRANSIENT IMMUNOSUPPRESSION | FACTOR-IX | GENETICS & HEREDITY | TRANSGENE PRODUCT | specific immunity | Immune System - physiology | Genetic Vectors - administration & dosage | Genetic Vectors - immunology | Humans | DNA, Bacterial - immunology | Immunosuppression | Animals | Leukocytes, Mononuclear - immunology | Adenoviridae - genetics | Antibodies, Bacterial - immunology | Adenoviridae - immunology | Transduction, Genetic - methods | Cytokines - immunology | Genetic Therapy - adverse effects | Genetic Therapy - methods | Physiological aspects | Immune response | Genetic vectors | Gene therapy | Health aspects
Journal Article
Gene Therapy, ISSN 0969-7128, 2012, Volume 19, Issue 1, pp. 49 - 60
The corticospinal tract (CST) is extensively used as a model system for assessing potential therapies to enhance neuronal regeneration and functional recovery...
spinal cord injury | AAV | corticospinal tract | transduction | integration-deficient lentiviral vector | MOUSE-BRAIN | MEDICINE, RESEARCH & EXPERIMENTAL | PYRAMIDAL TRACT | NEUROTROPHIC FACTOR | AXON-REGENERATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | EFFICIENT GENE DELIVERY | CORTICAL-NEURONS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | SPINAL-CORD-INJURY | CENTRAL-NERVOUS-SYSTEM | VESICULAR STOMATITIS-VIRUS | PARKINSONS-DISEASE | Dependovirus - genetics | Genetic Therapy | Microglia - metabolism | Cell Count | Humans | Neurons - cytology | Lentivirus - metabolism | Transfection - methods | HEK293 Cells | Pyramidal Tracts - metabolism | Lentivirus - genetics | Neurons - metabolism | Serotyping | Astrocytes - cytology | Microglia - cytology | Gene Transfer Techniques | Green Fluorescent Proteins - metabolism | Dependovirus - metabolism | Genetic Vectors - metabolism | Rats | Dependovirus - classification | Virus Integration | Rats, Sprague-Dawley | Genetic Vectors - genetics | Animals | Pyramidal Tracts - cytology | Astrocytes - metabolism | Care and treatment | Neurons | Physiological aspects | Spinal cord injuries | Research | Gene therapy | Health aspects | Risk factors | Comparative studies | Transducers | Models | Vector space | Tropism | Regeneration | Central nervous system | Green fluorescent protein | Oligodendrocytes | Recovery of function | Serotypes | Pyramidal tracts | Spinal cord injury | Expression vectors
spinal cord injury | AAV | corticospinal tract | transduction | integration-deficient lentiviral vector | MOUSE-BRAIN | MEDICINE, RESEARCH & EXPERIMENTAL | PYRAMIDAL TRACT | NEUROTROPHIC FACTOR | AXON-REGENERATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | EFFICIENT GENE DELIVERY | CORTICAL-NEURONS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | SPINAL-CORD-INJURY | CENTRAL-NERVOUS-SYSTEM | VESICULAR STOMATITIS-VIRUS | PARKINSONS-DISEASE | Dependovirus - genetics | Genetic Therapy | Microglia - metabolism | Cell Count | Humans | Neurons - cytology | Lentivirus - metabolism | Transfection - methods | HEK293 Cells | Pyramidal Tracts - metabolism | Lentivirus - genetics | Neurons - metabolism | Serotyping | Astrocytes - cytology | Microglia - cytology | Gene Transfer Techniques | Green Fluorescent Proteins - metabolism | Dependovirus - metabolism | Genetic Vectors - metabolism | Rats | Dependovirus - classification | Virus Integration | Rats, Sprague-Dawley | Genetic Vectors - genetics | Animals | Pyramidal Tracts - cytology | Astrocytes - metabolism | Care and treatment | Neurons | Physiological aspects | Spinal cord injuries | Research | Gene therapy | Health aspects | Risk factors | Comparative studies | Transducers | Models | Vector space | Tropism | Regeneration | Central nervous system | Green fluorescent protein | Oligodendrocytes | Recovery of function | Serotypes | Pyramidal tracts | Spinal cord injury | Expression vectors
Journal Article
Current Opinion in Neurology, ISSN 1350-7540, 10/2015, Volume 28, Issue 5, pp. 522 - 527
Purpose of review Gene therapy as a treatment for neuromuscular disease has significantly advanced over the past decade. In the present review, the progress of...
Cas9/CRISPR | Adeno-associated viruses | Dystrophin | Duchenne muscular dystrophy | CELLS | MUSCULAR-DYSTROPHY | dystrophin | MODEL | NEUROSCIENCES | CLINICAL NEUROLOGY | RESPONSES | adeno-associated viruses | VASCULAR DELIVERY | AAV | MUSCLE FUNCTION | MICE | EXPRESSION | Dependovirus - genetics | Genetic Vectors - therapeutic use | Muscular Dystrophy, Duchenne - therapy | Humans | Genetic Therapy - methods | CRISPR | Cas9
Cas9/CRISPR | Adeno-associated viruses | Dystrophin | Duchenne muscular dystrophy | CELLS | MUSCULAR-DYSTROPHY | dystrophin | MODEL | NEUROSCIENCES | CLINICAL NEUROLOGY | RESPONSES | adeno-associated viruses | VASCULAR DELIVERY | AAV | MUSCLE FUNCTION | MICE | EXPRESSION | Dependovirus - genetics | Genetic Vectors - therapeutic use | Muscular Dystrophy, Duchenne - therapy | Humans | Genetic Therapy - methods | CRISPR | Cas9
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2019, Volume 14, Issue 3, p. e0212811
Adeno-associated virus (AAV) vectors represent promising candidates for gene therapy; however, pre-existing neutralizing antibodies (NAb) may reduce AAV vector...
AAV VECTORS | NEUTRALIZING ANTIBODIES | SAFETY | IMMUNE-RESPONSES | MULTIDISCIPLINARY SCIENCES | FACTOR-IX | LIVER | HUMORAL IMMUNITY | ANIMAL-MODELS | TRANSDUCTION | PHASE-I | Cats | Usage | Genetic vectors | Analysis | Outcome and process assessment (Health Care) | Genetic research | Genetic aspects | Dependoviruses | Gene therapy | Health aspects | Viral antibodies | Genes | Antibodies | Biopharmaceutics | Animal models | Immunoglobulins | Congenital diseases | Disease | Laboratories | Galactosidase | Clinical trials | Viruses | Monkeys & apes | Vectors (Biology) | Studies | Serotypes | In vivo methods and tests | Expression vectors
AAV VECTORS | NEUTRALIZING ANTIBODIES | SAFETY | IMMUNE-RESPONSES | MULTIDISCIPLINARY SCIENCES | FACTOR-IX | LIVER | HUMORAL IMMUNITY | ANIMAL-MODELS | TRANSDUCTION | PHASE-I | Cats | Usage | Genetic vectors | Analysis | Outcome and process assessment (Health Care) | Genetic research | Genetic aspects | Dependoviruses | Gene therapy | Health aspects | Viral antibodies | Genes | Antibodies | Biopharmaceutics | Animal models | Immunoglobulins | Congenital diseases | Disease | Laboratories | Galactosidase | Clinical trials | Viruses | Monkeys & apes | Vectors (Biology) | Studies | Serotypes | In vivo methods and tests | Expression vectors
Journal Article
7.
Full Text
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Journal of Clinical Investigation, ISSN 0021-9738, 02/2015, Volume 125, Issue 2, pp. 870 - 880
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number...
MEDICINE, RESEARCH & EXPERIMENTAL | AAV VECTORS | MURINE MODEL | HEPATOCELLULAR-CARCINOMA | INTEGRATION SITES | MOUSE MODEL | LIVER | LARGE-SCALE | INSERTIONAL MUTAGENESIS | METHYLMALONIC ACIDEMIA | LEBERS CONGENITAL AMAUROSIS | Transduction, Genetic | Liver Neoplasms - genetics | Pregnancy Proteins - genetics | Liver Neoplasms - therapy | Pregnancy Proteins - metabolism | Dependovirus | Animals | Mice, Mutant Strains | Carcinoma, Hepatocellular - genetics | Liver Neoplasms - metabolism | Carcinoma, Hepatocellular - therapy | Mice | Genetic Vectors | Carcinoma, Hepatocellular - metabolism | Genetic Therapy - methods | Usage | Liver diseases | Genetic vectors | Patient outcomes | Dependoviruses | Gene therapy | Properties | Risk factors | Studies | Rodents | Liver | MicroRNAs | Software | Genomes | Gene expression | Tumors
MEDICINE, RESEARCH & EXPERIMENTAL | AAV VECTORS | MURINE MODEL | HEPATOCELLULAR-CARCINOMA | INTEGRATION SITES | MOUSE MODEL | LIVER | LARGE-SCALE | INSERTIONAL MUTAGENESIS | METHYLMALONIC ACIDEMIA | LEBERS CONGENITAL AMAUROSIS | Transduction, Genetic | Liver Neoplasms - genetics | Pregnancy Proteins - genetics | Liver Neoplasms - therapy | Pregnancy Proteins - metabolism | Dependovirus | Animals | Mice, Mutant Strains | Carcinoma, Hepatocellular - genetics | Liver Neoplasms - metabolism | Carcinoma, Hepatocellular - therapy | Mice | Genetic Vectors | Carcinoma, Hepatocellular - metabolism | Genetic Therapy - methods | Usage | Liver diseases | Genetic vectors | Patient outcomes | Dependoviruses | Gene therapy | Properties | Risk factors | Studies | Rodents | Liver | MicroRNAs | Software | Genomes | Gene expression | Tumors
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/2009, Volume 157, Issue 2, pp. 153 - 165
In the late 1970s, it was predicted that gene therapy would be applied to humans within a decade. However, despite some success, gene therapy has still not...
vectors production | AAV | cell targeting | gene therapy | HSV | pseudotyping | lentivectors | transcriptional targeting | viral vectors | Lentivectors | Ad | Vectors production | Transcriptional targeting | Viral vectors | Gene therapy | Pseudotyping | Cell targeting | EFFICIENT GENE-TRANSFER | SEVERE COMBINED IMMUNODEFICIENCY | RECOMBINANT ADENOASSOCIATED VIRUS | ENGINEERED LENTIVIRAL VECTORS | THYMIDINE KINASE GENE | DEPENDENT ADENOVIRAL VECTORS | HSV-1 AMPLICON VECTORS | MURINE LEUKEMIA-VIRUS | TARGETED RETROVIRAL VECTORS | PHARMACOLOGY & PHARMACY | TRANSDUCE AIRWAY EPITHELIA | Genetic Therapy | Animals | Viruses - genetics | Genetic Vectors | Transgenes | Humans | Reviews | Themed Section
vectors production | AAV | cell targeting | gene therapy | HSV | pseudotyping | lentivectors | transcriptional targeting | viral vectors | Lentivectors | Ad | Vectors production | Transcriptional targeting | Viral vectors | Gene therapy | Pseudotyping | Cell targeting | EFFICIENT GENE-TRANSFER | SEVERE COMBINED IMMUNODEFICIENCY | RECOMBINANT ADENOASSOCIATED VIRUS | ENGINEERED LENTIVIRAL VECTORS | THYMIDINE KINASE GENE | DEPENDENT ADENOVIRAL VECTORS | HSV-1 AMPLICON VECTORS | MURINE LEUKEMIA-VIRUS | TARGETED RETROVIRAL VECTORS | PHARMACOLOGY & PHARMACY | TRANSDUCE AIRWAY EPITHELIA | Genetic Therapy | Animals | Viruses - genetics | Genetic Vectors | Transgenes | Humans | Reviews | Themed Section
Journal Article
Gene Therapy, ISSN 0969-7128, 10/2015, Volume 22, Issue 10, pp. 811 - 821
Lack of axon growth ability in the central nervous system poses a major barrier to achieving functional connectivity after injury. Thus, a non-transgenic...
RNA INTERFERENCE | MEDICINE, RESEARCH & EXPERIMENTAL | GANGLION-CELL AXONS | NEUROTROPHIC FACTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | AAV-MEDIATED EXPRESSION | SUPERIOR COLLICULUS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VIVO | GENETICS & HEREDITY | CORTICOSPINAL TRACT | SPINAL-CORD-INJURY | ADULT HAMSTERS | GENE-THERAPY | Nerve Regeneration - genetics | Neurogenesis - genetics | Optic Nerve Injuries - genetics | PTEN Phosphohydrolase - genetics | RNA, Small Interfering - genetics | Optic Nerve - physiology | Animals | Mice | Dependovirus | Genetic Vectors | RNA, Small Interfering - administration & dosage | Optic Nerve Injuries - therapy | Regeneration | Growth | Physiological aspects | Nervous system | Genetic aspects | Research | Ciliary neurotrophic factor | Cellular biology | Injuries | PTEN | Axon injury | Axon guidance | Axon regeneration | Retinal ganglion cell
RNA INTERFERENCE | MEDICINE, RESEARCH & EXPERIMENTAL | GANGLION-CELL AXONS | NEUROTROPHIC FACTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | AAV-MEDIATED EXPRESSION | SUPERIOR COLLICULUS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VIVO | GENETICS & HEREDITY | CORTICOSPINAL TRACT | SPINAL-CORD-INJURY | ADULT HAMSTERS | GENE-THERAPY | Nerve Regeneration - genetics | Neurogenesis - genetics | Optic Nerve Injuries - genetics | PTEN Phosphohydrolase - genetics | RNA, Small Interfering - genetics | Optic Nerve - physiology | Animals | Mice | Dependovirus | Genetic Vectors | RNA, Small Interfering - administration & dosage | Optic Nerve Injuries - therapy | Regeneration | Growth | Physiological aspects | Nervous system | Genetic aspects | Research | Ciliary neurotrophic factor | Cellular biology | Injuries | PTEN | Axon injury | Axon guidance | Axon regeneration | Retinal ganglion cell
Journal Article
Annual Review of Biomedical Engineering, ISSN 1523-9829, 12/2015, Volume 17, Issue 1, pp. 63 - 89
In a range of human trials, viral vectors have emerged as safe and effective delivery vehicles for clinical gene therapy, particularly for monogenic recessive...
genotoxicity | retrovirus | adeno-associated virus | vector engineering | adenovirus | lentivirus | Retrovirus | Adeno-Associated virus | Vector engineering | Adenovirus | Lentivirus | Genotoxicity | INTEGRATION SITE SELECTION | TARGETED ONCOLYTIC POXVIRUS | ENGINEERING, BIOMEDICAL | DIRECTED EVOLUTION | RETROVIRAL VECTORS | CALCIUM UP-REGULATION | MOUSE MODEL | ADENOASSOCIATED VIRUS AAV | PHASE-I | CYSTIC-FIBROSIS GENE | PARKINSONS-DISEASE | Dependovirus - genetics | Immunologic Deficiency Syndromes - therapy | Genetic Engineering | Retroviridae - genetics | Humans | Translational Medical Research | Lentivirus - genetics | Clinical Trials as Topic | Genetic Vectors | Genetic Therapy - methods | Genetic vectors | Genetic aspects | Host-virus relationships | Gene therapy | Observations | Genetic translation | Methods
genotoxicity | retrovirus | adeno-associated virus | vector engineering | adenovirus | lentivirus | Retrovirus | Adeno-Associated virus | Vector engineering | Adenovirus | Lentivirus | Genotoxicity | INTEGRATION SITE SELECTION | TARGETED ONCOLYTIC POXVIRUS | ENGINEERING, BIOMEDICAL | DIRECTED EVOLUTION | RETROVIRAL VECTORS | CALCIUM UP-REGULATION | MOUSE MODEL | ADENOASSOCIATED VIRUS AAV | PHASE-I | CYSTIC-FIBROSIS GENE | PARKINSONS-DISEASE | Dependovirus - genetics | Immunologic Deficiency Syndromes - therapy | Genetic Engineering | Retroviridae - genetics | Humans | Translational Medical Research | Lentivirus - genetics | Clinical Trials as Topic | Genetic Vectors | Genetic Therapy - methods | Genetic vectors | Genetic aspects | Host-virus relationships | Gene therapy | Observations | Genetic translation | Methods
Journal Article